Following nephrectomy for renal cell carcinoma with lymph node involvement, patients have a 5-year survival rate of only 28%, a new study found.
Superiority of the regimen was shown in intermediate- and poor-risk groups, as well as in intention-to-treat populations.
Conditional survival may more accurately assess prognosis than traditional survival for patients with metastatic kidney cancer, but the metric is not without its caveats.
A retrospective study compared older patients with mRCC with younger ones to determine if age and potential comorbidities is a barrier to clinical trial participation.
Among patients with pT1b renal cell carcinoma, cryoablation is associated with a 2.5-fold higher 5-year cancer-specific mortality rate compared with partial nephrectomy, a study found.